Entry into a Material Definitive Agreement The information set forth in

Chief Financial Officer — Rachel Vaknin: Salary increase for the Chief Financial Officer.

Regulation FD Disclosure. On June 16, 2026, Microbot Medical Inc. (the “Company”) issued a press release announcing that it has entered into a vendor agreement with Lovell Government Services, which creates an opportunity to sell the Company’s LIBERTY ® Endovascular Robotic System at more than 2,000 U.S. government facilities. The press release, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, is incorporated herein by reference. The information in this

Other Events. Microbot Medical Inc. (the “Company”) previously entered into an At the Market Offering Agreement dated June 10, 2021, as amended on July 1, 2024 (the “Sales Agreement”), with H.C. Wainwright & Co., LLC (“ Wainwright”) in connection with the Company’s “at the market offering” program (the “ATM Program”). Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through Wainwright the Company’s common stock (“Common Stock”), par value $0.01 per share (t…

The company increased salaries and bonuses for several key executives.

Entry into a Material Definitive Agreement The information set forth in

Regulation FD Disclosure. On November 26, 2025, Microbot Medical Inc. (the “Company”) issued a press release announcing that Atlanta-based Emory University Hospital has become the first hospital in the world to adopt the Company’s LIBERTY ® Endovascular Robotic System for patient care. Additionally, the Company is collaborating with Emory to establish an Endovascular Robotics Program in interventional radiology. The press release, which is furnished as Exhibit 99.1 to this Current Report on F…

The filing describes the granting of special one-time cash bonuses to certain executive officers and non-management board members.

Entry into a Material Definitive Agreement. On September 14, 2025, Microbot Medical Inc., a Delaware corporation (the “Company”), entered into an inducement agreement (the “Letter Agreement”) with certain holders (the “Holders”) of existing (i) series F preferred investment options to purchase 207,224 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), (ii) series G preferred investment options to purchase 628,571 shares of Common Stock, (iii) series H prefer…

Unregistered Sales of Equity Securities. The Company issued the New PIOs and the Wainwright PIOs pursuant to the exemption from the registration requirements of the Securities Act available under Section 4(a)(2). Neither the issuance of the New PIOs, the Wainwright PIOs, the New PIO Shares nor the share underlying the Wainwright PIOs have been registered under the Securities Act and such securities may not be offered or sold in the United States absent registration or an exemption from regist…

Unregistered Sales of Equity Securities. From August 26, 2025 through August 27, 2025, Microbot Medical Inc. (the “Company”) issued an aggregate of 4,055,870 shares (the “Shares”) of its common stock, par value $0.01 per share (the “Common Stock”), upon the exercise of (a) 300,000 outstanding Series H preferred investment options (the “Series H Options”), by the holders of the Series H Options and (b) 3,755,870 outstanding Series I preferred investment options (the “Series I Options”), by the…

Unregistered Sales of Equity Securities. From August 11, 2025 through August 25, 2025, Microbot Medical Inc. (the “Company”) issued an aggregate of 2,967,953 shares (the “Shares”) of its common stock, par value $0.01 per share (the “Common Stock”), upon the exercise of (a) 104,103 outstanding Series E preferred investment options (the “Series E Options”), by the holders of the Series E Options, (b) 467,144 outstanding Series G preferred investment options (the “Series G Options”), by the hold…

Unregistered Sales of Equity Securities. From July 29, 2025 through August 1, 2025, Microbot Medical Inc. (the “Company”) issued an aggregate of 4,344,286 shares of its common stock, par value $0.01 per share (the “Shares”), upon the exercise of outstanding Series G preferred investment options (the “Series G Options”), by the holders of the Series G Options. The exercise price per share of the Series G Options was $1.75, generating gross proceeds to the Company, before deducting placement ag…

Unregistered Sales of Equity Securities. Since July 17, 2025, Microbot Medical Inc. (the “Company”) issued an aggregate of 2,395,715 shares of its common stock, par value $0.01 per share (the “Shares”), upon the exercise outstanding Series G preferred investment options (the “Series G Options”), by the holders of the Series G Options. The exercise price per share of the Series G Options was $1.75, generating gross proceeds to the Company, before deducting placement agent fees and expenses, of…

Unregistered Sales of Equity Securities. Since June 18, 2025, Microbot Medical Inc. (the “Company”) issued an aggregate of 1,808,336 shares of its common stock, par value $0.01 per share (the “Shares”), upon the exercise of an aggregate of 1,025,000 outstanding Series G preferred investment options (the “Series G Options”) and 783,336 Series F preferred investment options (the “Series F Options” and, collectively with the Series G Options, the “Options”), by the holders of the Options. The ex…

Unregistered Sales of Equity Securities. Since May 13, 2025, Microbot Medical Inc. (the “Company”) issued an aggregate of 1,480,504 shares of its common stock, par value $0.01 per share (the “Shares”), upon the exercise of an aggregate of 221,062 outstanding Series E preferred investment options (the “Series E Options”) and 1,259,442 Series F preferred investment options (the “Series F Options” and, collectively with the Series E Options, the “Options”), by the holders of the Options. The exe…

Material Modification to Rights of Security Holders. On June 10, 2025 (the “Effective Time”), in keeping with stockholder approval obtained at the 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of Microbot Medical Inc. (the “Company”), discussed further below in this Current Report on Form 8-K, the Company filed with the State of Delaware a Certificate of Amendment to the Company’s Restated Certificate of Incorporation, as amended, which increased the total number of shares of com…

Unregistered Sales of Equity Securities. On April 21, 2025, Microbot Medical Inc. (the “Company”) issued an aggregate of 1,533,336 shares of its common stock, par value $0.01 per share (the “Shares”), upon the exercise of 783,336 outstanding Series F preferred investment options and 750,000 Series E preferred investment options (collectively, the “Options”), by the holders of the Options. The exercise price per share of the Options was $1.50, generating gross proceeds to the Company, before d…

Material Modification to Rights of Security Holders. The information set forth under

Regulation FD Disclosure. On February 25, 2025, Microbot Medical Inc. (the “Company”) issued a press release announcing that its research collaboration with Corewell Health™ demonstrates the feasibility of using the LIBERTY ® Endovascular Robotic System between separate and remote facilities in a coronary simulation model. The project assesses the feasibility of using LIBERTY ® to perform simulated cardiovascular interventional procedures across two sites within the Corewell Health™ system lo…

Regulation FD Disclosure. On February 11, 2025, Microbot Medical Inc. (the “Company”) issued a press release announcing the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 6,103,289 shares of the Company’s common stock at a purchase price of $2.13 per share of common stock (the Registered Offering”). In addition, in a concurrent private placement, the Company issued unregistered short-term series I preferred i…

Other Events. On February 11, 2025, the Company closed the Registered Offering and the Private Placement.

Unregistered Sales of Equity Securities. The information set forth in

Entry into a Material Definitive Agreement. On February 9, 2025, Microbot Medical Inc., a Delaware corporation (the “Company”), entered into Securities Purchase Agreements (the “Purchase Agreements”) with investors (the “Investors”), pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of The Nasdaq Stock Market (the “Registered Offering”) an aggregate of 6,103,289 shares (the “Shares”) of the Company’s common stock, par…

Other Events. Overview Microbot Medical Inc. (the “Company”, “we” or “us”) is a clinical-stage medical device company specializing in the research, design and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. We are primarily focused on leveraging our robotic technologies with the goal of redefining surgical robotics while improving surgical outcomes for patients. Using our LIBERTY ® technological platform, we are developing the…